Nuria Ribelles - Concepedia

Author

Nuria Ribelles

Hospital Clínico Universitario Virgen de la Victoria ORCID

Also Known As

I Cuende, J Kather, M. Muñoz, Montserrat Muñoz, Muñoz, Montserrat, N Ribelles, N. Ribelles, NURIA RIBELLES, Nuria Ribelles, Palles, Claire

171

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínico Universitario Virgen de la Victoria Instituto de Investigación Biomédica de Málaga Universidad de Málaga Hospital Clínico San Carlos Hospital Universitario Virgen del Rocío

About

Nuria Ribelles is an author at Hospital Clínico Universitario Virgen de la Victoria specializing in oncology, medicine, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	31	2.4K
2	Health Sciences	10	10	1.2K
3	Engineering	5	5	780
4	Language Studies	1	1	29
5	Public Health	1	1	587

Nuria Ribelles

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Sandra M. Swain, David Miles, Sung‐Bae Kim, The Lancet Oncology End-of-study ResultsBreast OncologyMedicineClinical TrialsPathology	2020	854
Missing data imputation using statistical and machine learning methods in a real breast cancer problem José M. Jerez, Ignacio Molina, Pedro J. García-Laencina, Artificial Intelligence in Medicine EngineeringMachine LearningData MiningData ImputationPredictive Analytics	2010	587
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial Miguel Martín, Monserrat Muñoz, A. Balil, The Lancet Oncology Metastatic Breast CancerOncologyBreast OncologyMedicineBreast Cancer	2007	186
ESMO Guidance for Reporting Oncology real-World evidence (GROW) Luís Castelo-Branco, Anna Pellat, Diogo Martins-Branco, Annals of Oncology MedicineCancer ManagementCancer RegistrationEsmo GuidanceOncology	2023	183
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego, The Lancet Oncology Breast OncologyMedicineChemotherapy De-escalationPathologyImmune Checkpoint Inhibitor	2021	152
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study Emilio Alba, José Ignacio Chacón, Aňa Lluch, Breast Cancer Research and Treatment Neoadjuvant SettingOncologyBreast OncologyMedicinePlatinum Salts	2012	143
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index Nuria Ribelles, Lidia Pérez-Villa, José M. Jerez, Breast Cancer Research	2013	116
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) Thomas Bachelot, Eva Ciruelos, Fabio Puglisi, Annals of Oncology Metastatic Breast CancerBreast OncologyMedicinePathologyPreliminary Safety	2019	111
Predicting response and survival in chemotherapy-treated triple-negative breast cancer Aleix Prat, Aňa Lluch, Joan Albanell, British Journal of Cancer	2014	110
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay Aleix Prat, Patricia Galván, Begoña Jiménez, Clinical Cancer Research	2015	95

Page 1